EGFR and lung cancer: Four lung cancer cell lines (H292, H441, H358 and HCC827) were briefly exposed to erlotinib, an inhibitor of EGFR, or dasatinib, a SRC family kinase inhibitor that inhibits multiple tyrosine and serine/threonine kinases [37], [38], [39].